CHARLES RIVER LABORATORIES (CRL) Stock Fundamental Analysis
USA - NYSE:CRL - US1598641074 - Common Stock
178.73 USD
-1.34 (-0.74%)
CRL gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 58 industry peers in the Life Sciences Tools & Services industry. CRL has an average financial health and profitability rating. CRL has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
In the past year CRL was profitable.
CRL had a positive operating cash flow in the past year.
CRL had positive earnings in each of the past 5 years.
Each year in the past 5 years CRL had a positive operating cash flow.
1.2 Ratios
CRL has a Return On Assets of -0.92%. This is in the better half of the industry: CRL outperforms 60.34% of its industry peers.
The Return On Equity of CRL (-2.06%) is comparable to the rest of the industry.
CRL has a Return On Invested Capital of 5.72%. This is in the better half of the industry: CRL outperforms 74.14% of its industry peers.
CRL had an Average Return On Invested Capital over the past 3 years of 7.32%. This is significantly below the industry average of 13.51%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.92% | ||
| ROE | -2.06% | ||
| ROIC | 5.72% |
ROA(3y)4.11%
ROA(5y)4.9%
ROE(3y)9.94%
ROE(5y)12.5%
ROIC(3y)7.32%
ROIC(5y)7.6%
1.3 Margins
In the last couple of years the Profit Margin of CRL has declined.
CRL has a Operating Margin of 11.64%. This is in the better half of the industry: CRL outperforms 72.41% of its industry peers.
In the last couple of years the Operating Margin of CRL has remained more or less at the same level.
CRL has a worse Gross Margin (35.03%) than 62.07% of its industry peers.
CRL's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 11.64% | ||
| PM (TTM) | N/A | ||
| GM | 35.03% |
OM growth 3Y-8.72%
OM growth 5Y-1.4%
PM growth 3Y-71.55%
PM growth 5Y-51.64%
GM growth 3Y-2.67%
GM growth 5Y-1%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), CRL is destroying value.
Compared to 1 year ago, CRL has less shares outstanding
CRL has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, CRL has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 2.41 indicates that CRL is not a great score, but indicates only limited risk for bankruptcy at the moment.
With a Altman-Z score value of 2.41, CRL perfoms like the industry average, outperforming 58.62% of the companies in the same industry.
The Debt to FCF ratio of CRL is 4.04, which is a neutral value as it means it would take CRL, 4.04 years of fcf income to pay off all of its debts.
CRL has a better Debt to FCF ratio (4.04) than 70.69% of its industry peers.
CRL has a Debt/Equity ratio of 0.70. This is a neutral value indicating CRL is somewhat dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.70, CRL is doing worse than 72.41% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.7 | ||
| Debt/FCF | 4.04 | ||
| Altman-Z | 2.41 |
ROIC/WACC0.56
WACC10.27%
2.3 Liquidity
CRL has a Current Ratio of 1.36. This is a normal value and indicates that CRL is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.36, CRL is doing worse than 79.31% of the companies in the same industry.
CRL has a Quick Ratio of 1.10. This is a normal value and indicates that CRL is financially healthy and should not expect problems in meeting its short term obligations.
CRL has a worse Quick ratio (1.10) than 74.14% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.36 | ||
| Quick Ratio | 1.1 |
3. Growth
3.1 Past
CRL shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 4.49%.
Measured over the past years, CRL shows a quite strong growth in Earnings Per Share. The EPS has been growing by 8.93% on average per year.
CRL shows a decrease in Revenue. In the last year, the revenue decreased by -1.21%.
CRL shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 9.09% yearly.
EPS 1Y (TTM)4.49%
EPS 3Y-0.03%
EPS 5Y8.93%
EPS Q2Q%11.43%
Revenue 1Y (TTM)-1.21%
Revenue growth 3Y4.59%
Revenue growth 5Y9.09%
Sales Q2Q%0.59%
3.2 Future
Based on estimates for the next years, CRL will show a small growth in Earnings Per Share. The EPS will grow by 5.95% on average per year.
The Revenue is expected to grow by 2.43% on average over the next years.
EPS Next Y-0.31%
EPS Next 2Y2.66%
EPS Next 3Y4.69%
EPS Next 5Y5.95%
Revenue Next Year-0.98%
Revenue Next 2Y0.71%
Revenue Next 3Y2.15%
Revenue Next 5Y2.43%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 16.69 indicates a correct valuation of CRL.
CRL's Price/Earnings ratio is rather cheap when compared to the industry. CRL is cheaper than 94.83% of the companies in the same industry.
CRL is valuated rather cheaply when we compare the Price/Earnings ratio to 26.11, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 16.43 indicates a correct valuation of CRL.
Based on the Price/Forward Earnings ratio, CRL is valued cheaply inside the industry as 93.10% of the companies are valued more expensively.
The average S&P500 Price/Forward Earnings ratio is at 22.55. CRL is valued slightly cheaper when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.69 | ||
| Fwd PE | 16.43 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, CRL is valued cheaply inside the industry as 96.55% of the companies are valued more expensively.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of CRL indicates a rather cheap valuation: CRL is cheaper than 93.10% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 15.2 | ||
| EV/EBITDA | 12.25 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)1.87
EPS Next 2Y2.66%
EPS Next 3Y4.69%
5. Dividend
5.1 Amount
CRL does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NYSE:CRL (11/3/2025, 3:27:19 PM)
178.73
-1.34 (-0.74%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners105.46%
Inst Owner Change-2.2%
Ins Owners0.88%
Ins Owner Change6.15%
Market Cap8.80B
Revenue(TTM)4.03B
Net Income(TTM)-69225000
Analysts71.3
Price Target192.74 (7.84%)
Short Float %4.3%
Short Ratio2.29
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)17.56%
Min EPS beat(2)11.44%
Max EPS beat(2)23.68%
EPS beat(4)4
Avg EPS beat(4)11.21%
Min EPS beat(4)4.03%
Max EPS beat(4)23.68%
EPS beat(8)8
Avg EPS beat(8)10.55%
EPS beat(12)12
Avg EPS beat(12)8.62%
EPS beat(16)16
Avg EPS beat(16)6.82%
Revenue beat(2)2
Avg Revenue beat(2)3.59%
Min Revenue beat(2)3.45%
Max Revenue beat(2)3.74%
Revenue beat(4)4
Avg Revenue beat(4)2.63%
Min Revenue beat(4)0.91%
Max Revenue beat(4)3.74%
Revenue beat(8)7
Avg Revenue beat(8)1.68%
Revenue beat(12)10
Avg Revenue beat(12)1.88%
Revenue beat(16)11
Avg Revenue beat(16)1.12%
PT rev (1m)5.84%
PT rev (3m)20.01%
EPS NQ rev (1m)-0.35%
EPS NQ rev (3m)-1.61%
EPS NY rev (1m)-0.03%
EPS NY rev (3m)6.11%
Revenue NQ rev (1m)0.38%
Revenue NQ rev (3m)3.17%
Revenue NY rev (1m)0.1%
Revenue NY rev (3m)2.36%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.69 | ||
| Fwd PE | 16.43 | ||
| P/S | 2.18 | ||
| P/FCF | 15.2 | ||
| P/OCF | 11.17 | ||
| P/B | 2.62 | ||
| P/tB | N/A | ||
| EV/EBITDA | 12.25 |
EPS(TTM)10.71
EY5.99%
EPS(NY)10.88
Fwd EY6.08%
FCF(TTM)11.76
FCFY6.58%
OCF(TTM)16
OCFY8.95%
SpS81.87
BVpS68.14
TBVpS-3.77
PEG (NY)N/A
PEG (5Y)1.87
Graham Number128.14
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -0.92% | ||
| ROE | -2.06% | ||
| ROCE | 7.24% | ||
| ROIC | 5.72% | ||
| ROICexc | 5.88% | ||
| ROICexgc | 13.43% | ||
| OM | 11.64% | ||
| PM (TTM) | N/A | ||
| GM | 35.03% | ||
| FCFM | 14.36% |
ROA(3y)4.11%
ROA(5y)4.9%
ROE(3y)9.94%
ROE(5y)12.5%
ROIC(3y)7.32%
ROIC(5y)7.6%
ROICexc(3y)7.59%
ROICexc(5y)7.91%
ROICexgc(3y)18.25%
ROICexgc(5y)19.94%
ROCE(3y)9.27%
ROCE(5y)9.62%
ROICexgc growth 3Y-14.69%
ROICexgc growth 5Y-4.68%
ROICexc growth 3Y-7.59%
ROICexc growth 5Y-3.19%
OM growth 3Y-8.72%
OM growth 5Y-1.4%
PM growth 3Y-71.55%
PM growth 5Y-51.64%
GM growth 3Y-2.67%
GM growth 5Y-1%
F-Score4
Asset Turnover0.53
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.7 | ||
| Debt/FCF | 4.04 | ||
| Debt/EBITDA | 2.59 | ||
| Cap/Depr | 48.58% | ||
| Cap/Sales | 5.19% | ||
| Interest Coverage | 4.15 | ||
| Cash Conversion | 87.57% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.36 | ||
| Quick Ratio | 1.1 | ||
| Altman-Z | 2.41 |
F-Score4
WACC10.27%
ROIC/WACC0.56
Cap/Depr(3y)90.89%
Cap/Depr(5y)85.95%
Cap/Sales(3y)7.21%
Cap/Sales(5y)6.76%
Profit Quality(3y)1669.68%
Profit Quality(5y)1049.89%
High Growth Momentum
Growth
EPS 1Y (TTM)4.49%
EPS 3Y-0.03%
EPS 5Y8.93%
EPS Q2Q%11.43%
EPS Next Y-0.31%
EPS Next 2Y2.66%
EPS Next 3Y4.69%
EPS Next 5Y5.95%
Revenue 1Y (TTM)-1.21%
Revenue growth 3Y4.59%
Revenue growth 5Y9.09%
Sales Q2Q%0.59%
Revenue Next Year-0.98%
Revenue Next 2Y0.71%
Revenue Next 3Y2.15%
Revenue Next 5Y2.43%
EBIT growth 1Y-25.61%
EBIT growth 3Y-4.53%
EBIT growth 5Y7.56%
EBIT Next Year34.27%
EBIT Next 3Y14.36%
EBIT Next 5Y10.95%
FCF growth 1Y99.92%
FCF growth 3Y-1.94%
FCF growth 5Y8.06%
OCF growth 1Y25.98%
OCF growth 3Y-1.16%
OCF growth 5Y8.84%
CHARLES RIVER LABORATORIES / CRL FAQ
What is the fundamental rating for CRL stock?
ChartMill assigns a fundamental rating of 4 / 10 to CRL.
Can you provide the valuation status for CHARLES RIVER LABORATORIES?
ChartMill assigns a valuation rating of 6 / 10 to CHARLES RIVER LABORATORIES (CRL). This can be considered as Fairly Valued.
How profitable is CHARLES RIVER LABORATORIES (CRL) stock?
CHARLES RIVER LABORATORIES (CRL) has a profitability rating of 4 / 10.
What is the valuation of CHARLES RIVER LABORATORIES based on its PE and PB ratios?
The Price/Earnings (PE) ratio for CHARLES RIVER LABORATORIES (CRL) is 16.69 and the Price/Book (PB) ratio is 2.62.
How financially healthy is CHARLES RIVER LABORATORIES?
The financial health rating of CHARLES RIVER LABORATORIES (CRL) is 4 / 10.